|
NEW YORK (AP) - Human Genome Sciences Inc. said Thursday that a study showed its experimental drug for hepatitis C was well-tolerated and reduced the virus in some patients who hadn't been treated previously.
The trial for the drug called Albuferon involved 56 patients who were each given one of five doses of the drug. Patients were given two doses of the drug 14 days apart and were followed for safety and viral load evaluations for a total of six weeks.
Sixty-nine percent of the patients taking the two highest doses met the targeted viral load reduction on the 28th day of the study. The study was designed to look at the rate of viral load on the 28th day.
|